-

Innovaderm recognized by pharma and biotech sponsors as top performer champion, sweeping all categories of the 2023 CRO Leadership Awards

MONTREAL--(BUSINESS WIRE)--Innovaderm has been honored as a Champion of the 2023 CRO Leadership Awards, garnering top performer accolades across all core categories of Expertise, Capabilities, Quality, Reliability and Compatibility. By scoring as a top performer, in relation to the weighted average of other CROs included in ISR’s annual CRO Quality Benchmarking survey, Innovaderm has been awarded the additional designation of Champion.

Innovaderm is the leading dermatology CRO, built upon deep dermatology expertise and over 20 years of success, offering full-service capabilities across all phases of clinical trials, towards the goal of improving patient’s lives.

“CRO selection is one of the most important and strategic decision study sponsors must make for their clinical research programs. Winning organizations are selected in each of these categories based on the market research our colleagues at ISR Reports conducted with decision makers at study sponsor companies over the last 18 months. Congratulations to all the winners for your outstanding performance and vital contribution to the clinical research industry.” Amit Dua, Vice President, Market Development, Clinical Leader.

“We are very pleased to have been awarded this prestigious recognition for the third year in a row, by our clients and collaborators,” Dr. Robert Bissonnette, Founder and CEO of Innovaderm, commented. “It is a tremendous honor to see our work acknowledged by biotech and pharma sponsors. At Innovaderm, we pride ourselves on the excellence in the execution and delivery of high-quality services, in the interest of advancing scientific and medical research.”

To learn about Innovaderm’s services, visit our website.

Innovaderm Research Inc.

Innovaderm Research Inc. is the leading full-service dermatology CRO. Founded in 2000, Innovaderm’s deep expertise and experience enables the ability to operationalize all aspects of clinical research, and deliver excellence across early to late phase studies. Innovaderm’s mission is to drive innovative research initiatives towards the goal of improving patients’ lives.

Contacts

Mikael Leclaire
Marketing Coordinator
busdev@innovaderm.com

More News From Innovaderm

Indero Named Best Employer by Mercer

MONTREAL--(BUSINESS WIRE)--Indero, a global CRO specializing in dermatology and rheumatology, has been honored by Mercer, recognizing its excellence as a Best Employer. Indero is proud of its long-term commitment to building a workplace culture defined by trust, fairness, and meaningful employee experiences and believes this distinction reflects its positive impact in 2025. The Best Employers in Canada – Powered by Mercer certification program recognizes organizations that consistently deliver...

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression

MONTREAL--(BUSINESS WIRE)--Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our g...

Indero Celebrates 25 Years and Looks to the Future of Clinical Research

MONTREAL--(BUSINESS WIRE)--Indero, the niche CRO formerly known as Innovaderm, is celebrating 25 years of advancing clinical research. From its roots as a dermatology site in Montreal, Indero has grown into a global organization with capabilities in more than 30 countries across 4 continents and has earned a reputation for delivering expert, efficient trials in dermatology and, more recently, rheumatology. Indero was founded as Innovaderm in 2000, starting as a clinical site and now a global CR...
Back to Newsroom